Thyrocare Technologies (BOM:539871) Piotroski F-Score: 6 (As of Aug. 06, 2026) — 50% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539871 Thyrocare Technologies Ltd BOM:539871
87 GF Score
Price ₹599.95
GF Value ₹416.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Thyrocare Technologies Piotroski F-Score?

Thyrocare Technologies BOM:539871 -0.74% 87 Piotroski F-Score is 6 as of Aug. 06, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates BOM:539871 with a GF Score™ of 87/100 and a GF Value™ of ₹416.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 207 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 78.74% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Thyrocare Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Thyrocare Technologies's Piotroski F-Score or its related term are showing as below:

BOM:539871' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 7
Current: 6

During the past 13 years, the highest Piotroski F-Score of Thyrocare Technologies was 7. The lowest was 1. And the median was 4.

Thyrocare Technologies  (BOM:539871) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Thyrocare Technologies Piotroski F-Score Related Terms


Thyrocare Technologies Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Thyrocare Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thyrocare Technologies Piotroski F-Score Chart

Thyrocare Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 2.00 5.00 5.00 5.00

Thyrocare Technologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 6.00 5.00 6.00

BOM:539871 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Thyrocare Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thyrocare Technologies Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Thyrocare Technologies's Piotroski F-Score falls into.


BOM:539871
87GF Score
Thyrocare Technologies Ltd BOM:539871
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 479.9 + 290.1 + 471.2 + 521.9 = ₹1,763 Mil.
Cash Flow from Operations was 0 + 0 + 0 + 0 = ₹0 Mil.
Revenue was 2165.3 + 1955.3 + 2239.5 + 2400.2 = ₹8,760 Mil.
Gross Profit was 1564.7 + 1483.3 + 1672.7 + 1778.6 = ₹6,499 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(6927.5 + 0 + 6802.1 + 0 + 7472.2) / 5 = ₹7067.26666667 Mil.
Total Assets at the begining of this year (Jun25) was ₹6,928 Mil.
Long-Term Debt & Capital Lease Obligation was ₹392 Mil.
Total Current Assets was ₹3,723 Mil.
Total Current Liabilities was ₹1,099 Mil.
Net Income was 266.7 + 191.1 + 217 + 389.3 = ₹1,064 Mil.

Revenue was 1773.6 + 1659.2 + 1871.6 + 1930.3 = ₹7,235 Mil.
Gross Profit was 1263.7 + 1207.6 + 1376.9 + 1374 = ₹5,222 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(6438.8 + 0 + 5970.8 + 0 + 6927.5) / 5 = ₹6445.7 Mil.
Total Assets at the begining of last year (Jun24) was ₹6,439 Mil.
Long-Term Debt & Capital Lease Obligation was ₹169 Mil.
Total Current Assets was ₹3,377 Mil.
Total Current Liabilities was ₹1,218 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Thyrocare Technologies's current Net Income (TTM) was 1,763. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Thyrocare Technologies's current Cash Flow from Operations (TTM) was 0. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=1763.1/6927.5
=0.2545074

ROA (Last Year)=Net Income/Total Assets (Jun24)
=1064.1/6438.8
=0.16526371

Thyrocare Technologies's return on assets of this year was 0.2545074. Thyrocare Technologies's return on assets of last year was 0.16526371. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Thyrocare Technologies's current Net Income (TTM) was 1,763. Thyrocare Technologies's current Cash Flow from Operations (TTM) was 0. ==> 0 <= 1,763 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=391.8/7067.26666667
=0.05543869

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=169.2/6445.7
=0.02625006

Thyrocare Technologies's gearing of this year was 0.05543869. Thyrocare Technologies's gearing of last year was 0.02625006. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=3722.9/1099.1
=3.38722591

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=3377.2/1218.4
=2.77183191

Thyrocare Technologies's current ratio of this year was 3.38722591. Thyrocare Technologies's current ratio of last year was 2.77183191. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Thyrocare Technologies's number of shares in issue this year was 162.081. Thyrocare Technologies's number of shares in issue last year was 162.208. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=6499.3/8760.3
=0.74190382

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=5222.2/7234.7
=0.72182675

Thyrocare Technologies's gross margin of this year was 0.74190382. Thyrocare Technologies's gross margin of last year was 0.72182675. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=8760.3/6927.5
=1.26456875

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=7234.7/6438.8
=1.12360999

Thyrocare Technologies's asset turnover of this year was 1.26456875. Thyrocare Technologies's asset turnover of last year was 1.12360999. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+0+1+1+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Thyrocare Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Thyrocare Technologies (BOM:539871) has a Piotroski F-Score of 6 as of Aug. 06, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Thyrocare Technologies and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Thyrocare Technologies' Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Thyrocare Technologies ranks #44 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 21.3%.
Is Thyrocare Technologies' Piotroski F-Score too high?
Thyrocare Technologies' current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Thyrocare Technologies' value of 6 is 20% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #44 out of 207 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #44 out of 207 companies for Piotroski F-Score. This places Thyrocare Technologies in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Thyrocare Technologies' value of 6 is 20% above this benchmark. Historically, Thyrocare Technologies' own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (BOM:539871) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹416.05, compared to a current price of ₹599.95 — trading 44.2% above its estimated fair value. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 20% above the Medical Diagnostics & Research industry median of 5.00. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Thyrocare Technologies (BOM:539871), the current Piotroski F-Score is 6 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thyrocare Technologies (BOM:539871) Overvalued in 2026?

Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued. The current stock price of ₹599.95 is trading 44.2% above its estimated GF Value™ of ₹416.05. GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.

Key valuation signals for BOM:539871:

  • Piotroski F-Score: 6 (50% above median its 10-year median of 4.00)
  • GF Value™: ₹416.05 vs. price of ₹599.95 (44.2% above fair value)
  • GF Score™: 87/100 with 5 warning signs
  • Industry Position: 20% above the Medical Diagnostics & Research median (#44 of 207)

No single metric tells the full story. See the BOM:539871 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thyrocare Technologies Business Description

Other Exchanges THYROCARE:India
Address D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score

Get the complete analysis for BOM:539871

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹599.95
Price
₹416.05
GF Value